Drug Profile

INX 315

Alternative Names: INX-315

Latest Information Update: 26 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator G1 Therapeutics
Developer Incyclix Bio
Class Antineoplastics; Small molecules
Mechanism of Action Cyclin-dependent kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cancer

Most Recent Events

29 Apr 2025 INX 315 receives fast track status for Ovarian cancer (Late-stage disease, Second-line therapy or greater, Hormone-refractory, Metastatic disease) in USA
10 Jan 2025 Chemical structure information added.
13 Dec 2024 Efficacy and adverse event data from a phase I/II trial in Breast cancer released by Incyclix Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com